科室人员共主持国家自然基金：7  项 ，省部/市局及以上级课题近 30 项，累计经费 1000 余万元

主持国自然项目4项

●  国家自然基金委面上项目：基于多西他赛诱导三阴性乳腺癌全细胞抗原构建特异DC纳米疫苗的研究；82073387；55万；2021.01-2024.12；在研。

●  国家自然基金委地区科学基金项目：基于新药环巴胺的微环境响应自纳米化白蛋白-CD44双靶向PD-L1单抗纳米体系在三阴性乳腺癌中的作用及机制研究；81860547；34.8万；2019.01-2022.12；已结题。

●  国家自然基金委面上项目：热引导纳米化环巴胺靶向杀伤耐药性乳腺癌及作用机制；81573008；62.4 万；2016.01-2019.12；已结题。

●  国家自然青年基金委项目：基于纳米技术的联合生物治疗与化学药物治疗抗胰腺癌新策略―FAPα抗体－环巴胺－壳聚糖胶束；81201798；23万；2013.01-2015.12；已结题。

国家科技部重大专项子课题骨干1项

癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项：依据动态风险评估的乳腺癌分层筛查及干预策略；2025ZD0545404；252万元；2025.08-2029.07；在研。

主持省部级市局级20余项

●  2024年上海市东方英才领军人才：DFYCLJ02；60万，2024.01-2026.12；在研

●  2023年上海市科委优秀学术带头人：PD-1重编程TNBC细胞膜抗原的特异双致敏DC疫苗逆转免疫耐受的研究；23XD1402800；40万2023.05-2026.04；在研。

●  2022年上海市卫生健康委员会领军人才计划：肿瘤微环境影响乳腺癌抗PD-L1免疫治疗效果以及相互作用机制研究；2022LJ012；45万；2023.01-2025.12；在研。

●  2018年上海医学基金会“医苑新星”杰出青年医学人才计划；jcqnrc201901；20万；2019.01-2021.12；（结题后评优）。

 上海市浦东新区卫生和计划生育委员会领先人才培养项目：CREKA肿瘤微环境靶向的TNFα增强的PD-L1纳米制剂在三阴性乳腺癌治疗中的应用及机制研究；PWRl2019-07；40万；2019.10-2023.9；在研。

● 上海市浦东新区浦东新区卫生和计划生育委员会学科建设-重点专科：乳腺肿瘤；PWZzk2022-01；40万；2023.01—2026.12；在研。

●  上海市浦东新区卫计委行业专项：NK 细胞联合 PD-1 抑制剂+白蛋白紫杉醇治疗晚期非小细胞肺癌的临床试验研究；PW2021E-05；100万；2022.01-2024.12；在研。

发表学术论文

1. Fan T, Zhang M, Yang J, Zhu Z, Cao W*, Dong C*. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023 Dec 13;8(1):450. doi: 10.1038/s41392-023-01674-3. (Q1, IF:40.8) (通讯作者)

2. Qin W, Shao L, Li Q, Zhang D, Jia X, Dong C. ZNF526 drives tumor growth by enhancing SHMT1-dependent serine metabolism and antioxidant capability in TNBC. Mol Cancer. 2025 Nov 20;24(1):295. (Q1, IF:33.9) (通讯作者)

3. Chen L, Zhou LL, Wang CH, Han Y, Lu YL, Liu J, Hu XC, Yao TM, Lin Y, Liang SJ, Shi S*, Dong CY*. Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers. 2019, 31, 1904997, doi:10.1002/adma. 201904997. (Q1, IF:32.086) (通讯作者)

4. Ye Q, Lin Y, Li R, Wang H*, Dong C*. Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. Semin Cancer Biol. 2022 Nov;86(Pt 2):607-623. (Q1, IF:17.012)(通讯作者)

5. Zhao W, Hu X, Li W, Li R, Chen J, Zhou L, Qiang S, Wu W, Shi S*, Dong C*. M2-Like TAMs Function Reversal Contributes to Breast Cancer Eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy. Small. 2021 Apr;17(13):e2007051. (Q1, IF:15.153) (通讯作者)

6. Zhou L, Chen J, Li R, Wei L, Xiong H, Wang C, Chai K, Chen M, Zhu Z, Yao T, Lin Y, Dong C*, Shi S*. Metal-Polyphenol-Network Coated Prussian Blue Nanoparticles for Synergistic Ferroptosis and Apoptosis via Triggered GPX4 Inhibition and Concurrent In Situ Bleomycin Toxification. Small. 2021 Nov;17(47):e2103919.  (Q1, IF:15.153) (共同通讯作者)

7. Ye P, Wang C, Wen Y, Fang K, Li Q, Zhang X, Yang J, Li R, Chen M, Tong X, Shi S, Dong C. A positive-feedback loop suppresses TNBC tumour growth by remodeling tumour immune microenvironment and inducing ferroptosis. Biomaterials. 2025 Apr;315:122960. (Q1, IF:12.9) (通讯作者)

8. Hu XC, Li RH, Wu WJ, Fang K, Zhu ZN, Wang YX, Zhou LL, Chen MY, Dong CY*, and Shi S*. A Fe(III)-porphyrin-oxaliplatin(IV) nanoplatform for enhanced ferroptosis and combined therapy. Journal of Controlled Release. 2022 Jun 20;348:660-671. (Q1, IF:11.467) (共同通讯作者)

9. Rao Y, Fan T, Zhou L, Fang K, Sun Y, Hu X, Wang A, Li R, Zhu Z, Dong C*, Shi S*. A positive self-amplified H2O2 and acidity circulation for boosting CDT-PTT-starvation therapy. J Control Release. 2023 Feb;354:701-712. (Q1, IF:11.467) (共同通讯作者)

10. Hu X, Li H, Li R, Qiang S, Chen M, Shi S*, Dong C*. A Phase-Change Mediated Intelligent Nanoplatform for Chemo/Photothermal/Photodynamic Therapy of Cancer. Adv Healthc Mater. 2023 Feb;12(5):e2202245. (Q1, IF:11.092)(通讯作者）

11. Sun Y, Fang K, Hu X, Yang J, Jiang Z, Feng L, Li R, Rao Y, Shi S*, Dong C*. NIR-light-controlled G-quadruplex hydrogel for synergistically enhancing photodynamic therapy via sustained delivery of metformin and catalase-like activity in breast cancer. Mater Today Bio. 2022 Aug 1;16:100375. (Q1, IF:10.761)(通讯作者)

12. Li R, Hu X, Shang F, Wu W, Zhang H, Wang Y, Pan J, Shi S*, Dong C*. Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals. Acta Biomater. 2022 Aug;148:218-229. (Q1, IF:10.633) (通讯作者)

13. Feng L, Chen M, Li R, Zhou L, Wang C, Ye P, Hu X, Yang J, Sun Y, Zhu Z, Fang K, Chai K, Shi S*, Dong C*. Biodegradable oxygen-producing manganese-chelated metal organic frameworks for tumor-targeted synergistic chemo/photothermal/ photodynamic therapy. Acta Biomater. 2022 Jan; 138:463-477. (Q1, IF:10.633) (通讯作者)

14. Zhu H, Dong C, Dong H, Ren T, Wen X, Su J, Li Y*. Cleavable PEGylation and hydrophobic histidylation of polylysine for siRNA delivery and tumor gene therapy. ACS Appl Mater Interfaces. 2014 Jul 9;6(13):10393-407.（Q1,IF:10.383）（并列第一作者）

15. Chen M, Yang J, Zhou L, Hu X, Wang C, Chai K, Li R, Feng L, Sun Y, Dong C*, Shi S*. Dual-Responsive and ROS-Augmented Nanoplatform for Chemo/Photodynamic/Chemodynamic Combination Therapy of Triple Negative Breast Cancer. ACS Appl Mater Interfaces. 2022 Jan 12;14(1):57-68. (Q1, IF:10.383) (共同通讯作者)

16. Qiang S, Hu X, Li R, Wu W, Fang K, Li H, Sun Y, Liang S, Zhao W, Wang M, Lin Y, Shi S*, Dong C*. CuS Nanoparticles-Loaded and Cisplatin Prodrug Conjugated Fe(III)-MOFs for MRI-Guided Combination of Chemotherapy and NIR-II Photothermal Therapy. ACS Appl Mater Interfaces. 2022 Aug 17;14(32):36503-36514.(Q1, IF:10.383)(通讯作者）

17. Yang J, Wang C, Shi S*, Dong C*. Nanotechnologies for enhancing cancer immunotherapy. Nano Res. 2020, doi.org/10.1007/s12274-020-2904-8. (Q1, IF: 10.269) (通讯作者)

18. Zhou L, Chen J, Sun Y, Chai K, Zhu Z, Wang C, Chen M, Han W, Hu X, Li R, Yao T, Li H, Dong C*, Shi S*. A self-amplified nanocatalytic system for achieving "1 + 1 + 1 > 3" chemodynamic therapy on triple negative breast cancer. J Nanobiotechnology. 2021 Sep 4;19(1):261.(Q1, IF:10.2) (共同通讯作者)

19. Liu J, Hu X, Feng L, Lin Y, Liang S, Zhu Z, Shi S*, Dong C*. Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K/mTOR inhibitor and resists HIF-1α-dependent tumor hypoxia adaptation. J Nanobiotechnology. 2022 Apr 12;20(1):187.(Q1, IF: 10.2) (通讯作者)

20. Wang C, Ye P, Chen M, Li R, Wen Y, Wang Y, Tong X, Dong C, Shi S. Reducing the availability of endogenous copper and glucose for cascade starvation therapy and chemodynamic therapy. Mater Today Bio. 2025 Mar 24;32:101702. (Q1, IF: 10.2) (共同通讯作者)

21. Sun Y, Chen M, Ye P, Yang J, Fang K, Wang C, Li R, Fan T, Shi S, Dong C. Dual inhibition of DNA damage repair sensitizes photodynamic therapy for triple negative breast cancer. Mater Today Bio. 2025 Mar 24;32:101706.(Q1, IF: 10.2) (通讯作者)

22. Fang K, Sun Y, Yang J, Hu X, Chen M, Li R, Yang X, Fan T, Wu J, Tong X, Dong C*, Shi S*. A Dual Stimuli-Responsive Nanoplatform Loaded PtIV -Triptolide Prodrug for Achieving Synergistic Therapy toward Breast Cancer. Adv Healthc Mater. 2023 Jul 1:e2301328. （Q1, IF:10.0）（共同通讯作者）